CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) has announced the appointment of Dr. Bernhardt G. Zeiher to its Board of Directors. Dr. Zeiher is recognized for his extensive background in drug development, particularly in areas with significant unmet medical needs. With over two decades of experience, he has been instrumental in the approval of 15 new treatments during his tenure in the pharmaceutical industry.
The addition of Dr. Zeiher comes at a crucial time for Amylyx, as the company is actively engaged in developing new treatments for neurodegenerative diseases. His previous role as Chief Medical Officer at Astellas Pharma, where he led various facets of drug development, is expected to bring valuable insights to Amylyx's mission.
Throughout his career, Dr. Zeiher has held positions of increasing responsibility at Astellas, as well as at other major pharmaceutical companies such as Pfizer (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and Merck. His experience extends beyond corporate roles, having practiced medicine at a tertiary medical center and serving on several boards, including Entrada Therapeutics since 2023.
Amylyx Co-CEOs Joshua Cohen and Justin Klee expressed their enthusiasm for Dr. Zeiher's appointment, emphasizing the anticipated contributions to the company's upcoming milestones. These include the clinical development of their in-house developed antisense oligonucleotide AMX0114 for ALS and the continued research of AMX0035 for conditions such as Wolfram syndrome and progressive supranuclear palsy.
Dr. Zeiher's educational background includes a B.S. in biology from the University of Toledo and an MD from Case Western Reserve University School of Medicine. His post-graduate training was completed at University Hospitals of Cleveland and the University of Iowa Hospitals and Clinics.
Amylyx is focused on the discovery and development of novel treatments for neurodegenerative diseases and is based in Cambridge, Massachusetts, with operations extending to Canada, EMEA, and Japan.
This announcement is based on a press release statement and includes forward-looking statements subject to risks and uncertainties. Actual results may differ from those projected due to various risk factors. Amylyx has provided details on these risks in its filings with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.